Medicus Pharma Ltd. provides an update on the clinical development program for D-MNA to treat basal cell carcinoma of the skin.
FDA accepted the Type C meeting request, and the SKNJCT-003 Phase 2 study has randomized over 75% of patients.
The phase 2 clinical study aims to treat BCC using novel D-MNA with promising interim results.
FDA Approval Process
Type C meeting with the FDA to fast-track clinical development and gain feedback on future plans for D-MNA program.
Clinical Trial Design
SKNJCT-003 study is a randomized, double-blind, placebo-controlled trial with two D-MNA dose levels compared to placebo.
Phase 1 Success
SKNJCT-001 demonstrated safety and tolerability, with no serious adverse events and positive efficacy in BCC treatment.
Expansion Plans
Company expanding clinical trial sites in the U.S. and Europe, with ongoing studies in the United Arab Emirates.
Acquisition Announcement
Medicus Pharma Ltd. entered into an agreement to acquire Antev Ltd., a UK-based biotech company developing innovative products for prostate cancer and enlarged prostate.
- The acceptance of the Type C meeting request signifies progress in the regulatory approval process for D-MNA.
- Positive interim analysis results in the SKNJCT-003 study indicate potential efficacy in treating BCC non-invasively.
- Expansion of clinical trial sites in the U.S. and Europe shows the company's commitment to global research and development.
Medicus Pharma Ltd. is advancing its innovative D-MNA program for basal cell carcinoma treatment, with positive developments in clinical trials and strategic expansions. The company's focus on disruptive therapeutic assets and global collaborations position it for future success in the biotech industry.